睿知中国医院研究地图
候选清单

即将招募胰腺癌III期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

HRS-4642 Combined With Antitumor Agents for the Treatment of Perioperative Pancreatic Cancer

ClinicalTrials.gov 上登记的一项胰腺癌开放试验。牵头方不是本站收录的医院;本站收录的 2 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 2

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 研究中心北京协和医院Peking Union Medical College Hospital北京医院页面
  2. 研究中心上海交通大学医学院附属瑞金医院Ruijin Hospital上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07900789,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. Histologically or cytologically confirmed pancreatic cancer originating from the pancreatic ductal epithelium.

    入选标准第 5 条

  3. Received systemic immunosuppressive therapy within 14 days prior to randomization.

    排除标准第 5 条

    Gastrointestinal obstruction within 6 months prior to initiation of study treatment, or current signs and symptoms of gastrointestinal obstruction.

    排除标准第 8 条

    Major surgery (other than diagnostic procedure or biopsy) within 28 days prior to randomization; invasive minor surgery within 7 days prior to the first dose; or presence of a non-healing wound.

    排除标准第 21 条

  4. Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1.

    入选标准第 3 条

  5. At least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.

    入选标准第 7 条

  6. Diagnosis of any other malignancy within 5 years prior to randomization.

    排除标准第 12 条

    Active pulmonary tuberculosis infection within 1 year prior to enrollment.

    排除标准第 16 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);化验:血常规、肝肾功能;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07900789,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Able to provide informed consent, with a signed and dated IRB/EC-approved informed consent form (ICF), and willing and able to comply with the scheduled visits, treatment plan, examinations, and other protocol-required procedures.
  2. Aged between 18 and 75 years (inclusive) at the time of ICF signing; of either gender.
  3. Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1.
  4. Expected survival of at least 6 months.
  5. Histologically or cytologically confirmed pancreatic cancer originating from the pancreatic ductal epithelium.
  6. High-risk resectable pancreatic cancer (HR-RPC) or borderline resectable pancreatic cancer (BRPC).
  7. At least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.
  8. Adequate major organ function meeting the protocol-specified criteria.-

排除标准:Exclusion Criteria:

  1. Prior systemic therapy for pancreatic cancer, including neoadjuvant chemotherapy or radiotherapy.
  2. Distant metastatic lesions confirmed by imaging.
  3. Has not recovered from the toxicity and/or complications of prior interventions to NCI-CTCAE Grade ≤ 1 or the level specified in the inclusion/exclusion criteria.
  4. Currently has active autoimmune disease or a history of autoimmune disease with potential recurrence.
  5. Received systemic immunosuppressive therapy within 14 days prior to randomization.
  6. Known or suspected interstitial lung disease; or presence within 6 months prior to randomization of moderate-to-severe pulmonary diseases that may interfere with the detection or management of drug-related pulmonary toxicity or significantly impair respiratory function.
  7. Symptomatic moderate or severe ascites; uncontrolled or moderate-to-large pleural effusion or pericardial effusion.
  8. Gastrointestinal obstruction within 6 months prior to initiation of study treatment, or current signs and symptoms of gastrointestinal obstruction.
  9. Clinically significant bleeding episodes or a clear bleeding tendency within 6 months prior to randomization.
  10. Uncontrolled or severe cardiovascular/cerebrovascular disease, or arterial/venous thromboembolic events within 6 months prior to randomization; or arrhythmia, deep vein thrombosis, etc. requiring clinical intervention.
  11. Carotid ultrasound demonstrating ≥ 50% stenosis, or carotid plaques with ≥ 2 high-risk features.
  12. Diagnosis of any other malignancy within 5 years prior to randomization.
  13. Serious infection within 28 days prior to the first dose; or active infection requiring therapeutic intravenous antibiotics within 2 weeks prior to initiation of study treatment.
  14. Clinically significant acute or chronic pancreatitis.
  15. Active hepatitis B or active hepatitis C.
  16. Active pulmonary tuberculosis infection within 1 year prior to enrollment.
  17. History of immunodeficiency or organ transplantation.
  18. Active autoimmune disease requiring systemic treatment within 2 years prior to randomization.
  19. Administration of a live attenuated vaccine within 28 days prior to randomization, or anticipated need for live attenuated vaccination during study treatment.
  20. Participation in any other clinical drug trial within 4 weeks or 5 half-lives (whichever is longer) of the last study drug administration prior to randomization.
  21. Major surgery (other than diagnostic procedure or biopsy) within 28 days prior to randomization; invasive minor surgery within 7 days prior to the first dose; or presence of a non-healing wound.
  22. Known hypersensitivity to any component of HRS-4642; or known severe hypersensitivity to any of the combination antitumor agents (including SHR-1316, gemcitabine, and nab-paclitaxel).
  23. Uncontrolled psychiatric illness, or known alcoholism, drug abuse, substance dependence, criminal detention, or other conditions that may interfere with completion of study procedures.

引自 ClinicalTrials.gov, NCT07900789, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07900789,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07900789